[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643077":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":59,"centralContacts":63,"locations":11,"responsibleParty":71,"collaborators":73,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":11,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":11,"overallStatus":95,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":11},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,15,18,21,25,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Petrelintide + Enicepatide Dosing Regimen 1","EXPERIMENTAL",null,[13,14],"Drug: Petrelintide","Combination Product: Enicepatide",{"label":16,"type":10,"description":11,"interventionNames":17},"Arm 2: Petrelintide + Enicepatide Dosing Regimen 2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Arm 3: Petrelintide + Enicepatide Dosing Regimen 3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Arm 4: Petrelintide-matching Placebo + Enicepatide",[14,24],"Drug: Petrelintide-matching Placebo",{"label":26,"type":10,"description":11,"interventionNames":27},"Arm 5: Petrelintide + Enicepatide-matching Placebo",[13,28],"Combination Product: Enicepatide-matching Placebo",{"label":30,"type":31,"description":11,"interventionNames":32},"Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo","PLACEBO_COMPARATOR",[24,28],[34,42,51,55],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","Petrelintide","Petrelintide will be administered subcutaneously to participants once weekly",[9,16,19,26],[40,41],"RO7895515","ZP8396",{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"COMBINATION_PRODUCT","Enicepatide","Enicepatide will be administered subcutaneously to participants once weekly",[9,16,19,22],[48,49,50],"RO7795068","CT-388","RG6640",{"type":35,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"Petrelintide-matching Placebo","Matching placebo to Petrelintide will be administered subcutaneously to participants once weekly",[22,30],{"type":43,"name":56,"description":57,"armGroupLabels":58,"otherNames":11},"Enicepatide-matching Placebo","Matching placebo to Enicepatide will be administered subcutaneously to participants once weekly",[26,30],[60],{"name":61,"affiliation":5,"role":62},"Clinical Trials","STUDY_DIRECTOR",[64,69],{"name":65,"role":66,"phone":67,"phoneExt":11,"email":68},"Reference Study ID Number: CC46372 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":70,"role":66,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",{"type":72,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[74],{"name":75,"class":6},"Zealand Pharma","100643077","phase-2-a-dose-finding-study-of-petrelintide-with-enicepatide-ro7795068-in-adults-with-obesity-or-overweight-100643077",false,"NCT07589686","A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight","ZYNERGY","Key Inclusion Criteria:\n\n* Male or female participants with Body Mass Index (BMI) ≥ 30 kg\u002Fm² OR BMI ≥ 27 kg\u002Fm² to \\\u003C 30 kg\u002Fm² with at least one weight-related comorbidity\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nKey Exclusion Criteria:\n\n* HbA1c ≥ 48 mmol\u002Fmol (6.5%) at screening\n* History of Type 1 or Type 2 Diabetes\n* Self-reported change in body weight \\> 5 kg within 90 days prior to screening\n* Previous or planned obesity treatment with surgery (excluding liposuction, cryolipolysis, or abdominoplasty if performed \\> 1 year prior to or during screening)\n* Previous or planned endoscopic and\u002For device-based obesity treatment or removal or device within the last 6 months prior to screening (e.g., mucosal ablation, gastric artery embolization, intragastric balloon and duodenal-jejunal endoluminal liner)\n* Treatment with any GLP-1 receptor agonist, GLP-1\u002FGIP receptor agonist (or any other GLP-1 based treatment) within 180 days prior to or during screening\n* Current or previous treatment with petrelintide or any other amylin analog\n* Obesity induced by Cushing syndrome or a diagnosis of monogenetic or syndromic forms of obesity\n* History of severe psychiatric disorders\n* History of any hematologic conditions that may interfere with HbA1c measurement\n* Known history or presence of pancreatitis\n* Known clinically significant gastric emptying abnormality or chronic treatment that affects GI motility\n* New York Heart Association Functional Classification IV heart failure\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within the time frame in which contraception is required","ALL","18 Years",{"count":87,"type":88},486,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.",[94],"Obesity or Overweight","NOT_YET_RECRUITING","2026-06-10",{"date":98,"type":99},"2026-06-12","ACTUAL",{"date":101,"type":88},"2026-06-30",{"date":103,"type":88},"2028-01-31",{"name":5,"class":6}]